Circulating microRNAs as Promising Biomarkers in Parkinson's Disease
Specific blood microRNAs show promise as diagnostic markers for Parkinson's disease and correlate with symptom severity, though larger studies are needed to confirm clinical utility.
In 51 PD patients and 20 healthy controls, serum miR-24-3p shows significant diagnostic value (80.4% sensitivity, 85% specificity) and miR-331 correlates with disease severity (UPDRS scores); cross-platform multi-omics analysis identifies 21 differentially abundant miR-24-3p target proteins in PD CSF with metabolic pathway linkages. Despite small sample size, the multi-omics validation adds mechanistic depth beyond typical single-marker studies.
What the study was
- Study design
- case_control_biomarker_study
- Category
- aging_longevity_population
- Maturity
- Validated
- Journal
- Molecular Neurobiology
Why it surfaced
Circulating miRNA biomarkers for PD diagnosis with multi-omics cross-validation in a disease lacking reliable blood biomarkers; small cohort is a limitation. Score 5 (N=2, D=1, P=1, E=1) applying conservative small-cohort cap (n=51+20).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.